Physician profile
Muhammad Masab
NPI 1336522192
$5,059.54
in general payments reported to CMS, 2019-2025
45 companies · $2,437 in 2025
The $2,437 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.15 · 2021: $299 · 2022: $619 · 2023: $242 · 2024: $1,447 · 2025: $2,437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,070 · Education: $55.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,069.80 |
| Education | $55.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $486.42 | 2024-2025 | Injectafer, Enhertu, Datroway |
| Janssen Biotech, INC. | $373.88 | 2024-2025 | Darzalex, Talvey, Erleada |
| Abbvie INC. | $331.77 | 2022-2025 | |
| Genzyme Corporation | $287.39 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $268.36 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $256.78 | 2021-2025 | Lynparza, Calquence, Imfinzi |
| Merck Sharp & Dohme LLC | $209.46 | 2023-2025 | Keytruda, Welireg |
| Amgen INC. | $206.40 | 2019-2022 | |
| Eisai INC. | $167.90 | 2023-2025 | |
| Pfizer INC. | $163.42 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $155.17 | 2024-2025 | |
| Astellas Pharma US INC | $148.20 | 2024-2025 | Padcev, Xtandi, Vyloy |
| Incyte Corporation | $138.36 | 2024-2025 | Jakafi, Zynyz, Monjuvi |
| Alexion Pharmaceuticals, INC. | $131.67 | 2022-2025 | Ultomiris |
| Beone Medicines USA, INC. | $115.19 | 2025 | Brukinsa, Tevimbra |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $113.23 | 2025 | |
| Immunocore Limited | $104.44 | 2022-2024 | Kimmtrak |
| Seagen INC. | $99.00 | 2021 | |
| Sobi, INC | $98.97 | 2023-2025 | |
| Blueprint Medicines Corporation | $75.75 | 2024-2025 | Ayvakit |
| Beigene USA, INC. | $72.27 | 2023-2024 | Brukinsa |
| Amag Pharmaceuticals, INC. | $71.00 | 2021 | |
| Tempus Ai, INC | $70.54 | 2024-2025 | Xt Cdx |
| E.R. Squibb & Sons, L.L.C. | $70.13 | 2024-2025 | Opdivo, Krazati |
| Servier Pharmaceuticals LLC | $67.43 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $63.94 | 2024-2025 | Onivyde |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.44 | 2025 | |
| Genentech USA, INC. | $62.07 | 2025 | Venclexta |
| Novocure INC. | $60.03 | 2022 | |
| Taiho Oncology, INC. | $59.61 | 2025 | |
| Glaxosmithkline, LLC. | $57.48 | 2023-2025 | Ojjaara |
| Tersera Therapeutics LLC | $54.10 | 2024-2025 | Zoladex |
| Puma Biotechnology, INC. | $46.05 | 2024 | |
| Celgene Corporation | $41.18 | 2024-2025 | Reblozyl |
| Legend Biotech USA INC. | $36.24 | 2025 | Carvykti |
| Lilly USA, LLC | $36.16 | 2024-2025 | Verzenio, Jaypirca, Retevmo |
| Exelixis INC. | $32.77 | 2024-2025 | Cabometyx |
| Nestle Healthcare Nutrition INC. | $26.54 | 2023 | |
| Pharmacosmos Therapeutics INC. | $23.49 | 2025 | Monoferric |
| Array Biopharma INC | $23.12 | 2025 | Mektovi, Tukysa, Braftovi |
| Karyopharm Therapeutics INC. | $19.56 | 2025 | Xpovio |
| Adc Therapeutics America, INC. | $19.36 | 2024 | |
| Agios Pharmaceuticals, INC. | $18.36 | 2025 | Pyrukynd |
| Myriad Genetic Laboratories, INC. | $17.83 | 2024 | Myrisk |
| Gilead Sciences, INC. | $16.08 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Masab listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.